Milestone reflects growing adoption and reinforces the company’s mission to expand access to meaningful relief for patients suffering from chronic ENT conditions
Mountain View, Calif., March 25, 2026 – Aerin Medical Inc., a leader in minimally invasive solutions for chronic nasal conditions, today announced that more than 200,000 patients have been treated with Aerin’s RhinAer® and VivAer® temperature- and impedance-controlled radiofrequency technologies, marking a significant milestone in the adoption of these practical solutions for minimally invasive nasal procedures.
This achievement reflects the growing real-world impact of RhinAer and VivAer, as an increasing number of physicians integrate these solutions into their chronic rhinitis (CR) and nasal airway obstruction (NAO) treatment protocols. Clinical studies evaluating Aerin products have enrolled nearly 1,000 patients globally, contributing to a robust body of evidence demonstrating statistically significant and durable symptom improvement.
This progress reflects continued innovation, a strong foundation of clinical evidence, and a commitment to expanding patient access, supporting Aerin’s leadership in minimally invasive procedures for patients with CR and NAO.
“We celebrate this milestone alongside the otolaryngologists who have made it possible,” said Matt Brokaw, President and CEO of Aerin Medical. “Our close partnership with physicians enables the design of groundbreaking technology and the completion of rigorous clinical studies reflected in more than 40 peer-reviewed publications. That collaboration is now translating into expanding access to the treatment of appropriate patients. Patients and physicians are at the center of all that we do, and this milestone is particularly gratifying and motivating.”
About VivAer
VivAer is a minimally invasive technology that uses patented, temperature- and impedance-controlled radiofrequency energy and is clinically demonstrated to provide long-term relief from nasal obstruction. VivAer features a thin, wand-like stylus that attaches to an Aerin console. The stylus is inserted via the nostril to gently remodel the nasal tissue and improve airflow. VivAer does not involve cutting, removal of nasal tissue or bone, or the use of an implant. The procedure is performed in-office under local anesthesia, with no incisions and minimal downtime. The VivAer Stylus received CE Mark in 2016 and FDA 510(k) clearance in December 2017. For more information, visit www.VivAer.com.
About RhinAer
RhinAer is a minimally invasive technology that uses patented, temperature- and impedance-controlled radiofrequency energy and is clinically demonstrated to provide long-term relief from chronic rhinitis. RhinAer features a thin, wand-like stylus that attaches to an Aerin console. The stylus is inserted via the nostril to deliver precise therapeutic benefits to the posterior nasal nerve (PNN) and soft tissue, while sparing surrounding tissues. RhinAer directly disrupts the PNN that triggers excessive mucus production, treating an underlying cause of chronic rhinitis. RhinAer provides ENT physicians with a comprehensive solution for the treatment of chronic rhinitis, addressing sources of rhinorrhea and congestion. The procedure can be performed with a local anesthetic during an office visit, with no incisions, and minimal downtime. RhinAer received FDA 510(k) clearance in December 2019 and CE Mark in 2020. For more information, visit www.RhinAer.com.
About Aerin Medical
Aerin Medical is a privately held, venture-backed company, headquartered in Mountain View, California. Aerin’s mission is to expand access to meaningful relief for millions of patients suffering from chronic ENT conditions. The company’s products, VivAer® for nasal airway obstruction and RhinAer® for chronic rhinitis, leverage Aerin’s proprietary temperature-controlled technology, which allows ENT physicians to reliably improve patients’ symptoms with unique technologies that are appealing alternatives to invasive surgery. More than 200,000 patients have been treated with Aerin Medical products to date. For more information, please visit www.aerinmedical.com and follow Aerin Medical on Facebook, X, Instagram, LinkedIn and YouTube.
Media Contact:
Tasha Agharkar
Aerin Medical
tagharkar@aerinmedical.com
